Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT ID: NCT06144424
Last Updated: 2025-08-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
32 participants
INTERVENTIONAL
2023-10-25
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT04413942
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
NCT06723405
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
NCT04490109
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT07150845
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
NCT04992546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EP262 150 mg
Oral EP262
Once daily
Placebo
Placebo
Once Daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral EP262
Once daily
Placebo
Once Daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BSA of 3% to 20% and a vIGA-AD score of ≥3
Exclusion Criteria
* Clinically infected atopic dermatitis that requires antibiotic therapy
* Use of specific treatments for atopic dermatitis
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Escient Pharmaceuticals, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allervie Clinical Research
Birmingham, Alabama, United States
RM Medical Research, Inc.
Miami Lakes, Florida, United States
Indiana Clinical Trials Center
Plainfield, Indiana, United States
Lawrence J. Green, MD LLC
Rockville, Maryland, United States
Revival Research Institute, LLC
Troy, Michigan, United States
Optima Research Boardman
Boardman, Ohio, United States
J&S Studies, Inc.
College Station, Texas, United States
Jordan Valley Dermatology Center
South Jordan, Utah, United States
Dermatology Specialists of Spokane
Spokane, Washington, United States
Innovaderm Research Inc.
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EP-262-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.